Asia-Pacific antiviral drugs market is expected to reach USD 15,118.64 million by 2030 from USD 9,004.35 million in 2022, growing with a CAGR of 6.7% during the forecast period from 2023 to 2030. Market Segmentation: Asia-Pacific Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Country (China, Japan, India ,South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030. Overview of Asia-Pacific Antiviral Drugs Market Dynamics : Driver • Rising prevalence of viral infections Restrain • High cost of antiviral drugs Opportunity • Increasing collaboration and partnership among key players Market Players: Some of the key market players operating in the Asia-Pacific antiviral drugs market are listed below: • Gilead Sciences, Inc. • F. Hoffmann-La Roche Ltd • GLAXOSMITHKLINE PLC • Abbvie • Merck & Co., Inc. • Johnson & Johnson Services, Inc. • Bristol-Myers Squibb Company • Cipla Inc. • Aurobindo Pharma • Dr. Reddy’s Laboratories Ltd. • Zydus Pharmaceuticals, Inc. • Mylan Pharmaceuticals ULC • Teva Pharmaceuticals USA, Inc. • EMERGENT • Sun Pharmaceutical Industries Ltd. • Avet Pharmaceuticals Inc. • Pfizer Inc. • SIGA Technologies • NAVINTA LLC. • Macleods Pharmaceuticals Ltd. • BioCryst Pharmaceuticals, Inc • Hetero

1 INTRODUCTION 119 1.1 OBJECTIVES OF THE STUDY 119 1.2 MARKET DEFINITION 119 1.3 OVERVIEW OF THE ASIA-PACIFIC ANTIVIRAL DRUGS MARKET 119 1.4 LIMITATIONS 121 1.5 MARKETS COVERED 121 2 MARKET SEGMENTATION 127 2.1 MARKETS COVERED 127 2.2 GEOGRAPHICAL SCOPE 128 2.3 YEARS CONSIDERED FOR THE STUDY 129 2.4 CURRENCY AND PRICING 129 2.5 DBMR TRIPOD DATA VALIDATION MODEL 130 2.6 MULTIVARIATE MODELLING 133 2.7 PRODUCT TYPE LIFELINE CURVE 133 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134 2.9 DBMR MARKET POSITION GRID 135 2.10 MARKET TESTING TYPE COVERAGE GRID 136 2.11 VENDOR SHARE ANALYSIS 137 2.12 SECONDARY SOURCES 138 2.13 ASSUMPTIONS 138 3 EXECUTIVE SUMMARY 139 4 PREMIUM INSIGHTS 142 4.1 PORTER’S FIVE FORCES 145 4.2 PESTEL ANALYSIS 146 5 EPIDEMIOLOGY 147 6 PIPELINE ANALYSIS FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET 148 7 REGULATORY FRAMEWORK 149 8 MARKET OVERVIEW 151 8.1 DRIVERS 153 8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 153 8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 153 8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 155 8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 155 8.2 RESTRAINS 156 8.2.1 HIGH COST OF ANTIVIRAL DRUGS 156 8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 156 8.3 OPPORTUNITIES 157 8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 157 8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 157 8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 158 8.4 CHALLENGES 159 8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 159 8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 160 9 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION 161 9.1 OVERVIEW 162 9.2 INFLUENZA 165 9.2.1 NEURAMINIDASE INHIBITORS 166 9.2.1.1 OSELTAMIVIR 166 9.2.1.2 ZANAMIVIR 166 9.2.1.3 PERAMIVIR 166 9.2.1.4 LANINAMIVIR 166 9.2.2 M2 INHIBITORS 167 9.2.2.1 RIMANTADINE 167 9.2.2.2 OTHERS 167 9.2.3 RNA POLYMERASE INHIBITORS 167 9.2.3.1 FAVIPIRAVIR 167 9.2.3.2 BALOXAVIR MARBOXIL 167 9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 168 9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 169 9.3.1.1 NUCLEOSIDE (NRTIS) 169 9.3.1.1.1 LAMIVUDINE 170 9.3.1.1.2 ABACAVIR 170 9.3.1.1.3 DIDANOSINE 170 9.3.1.1.4 OTHERS 170 9.3.1.2 NONNUCLEOSIDE (NNRTIS) 170 9.3.1.2.1 EFAVIRENZ 170 9.3.1.2.2 NEVIRAPINE 170 9.3.1.2.3 DELAVIRDINE 170 9.3.1.2.4 OTHERS 171 9.3.1.3 INTEGRASE 171 9.3.1.3.1 DOLUTEGRAVIR 171 9.3.1.3.2 ELVITEGRAVIR 171 9.3.1.3.3 RALTEGRAVIR 171 9.3.1.3.4 BICTEGRAVIR 171 9.3.1.4 NUCLEOTIDE 171 9.3.1.4.1 TENOFOVIR 172 9.3.1.4.2 OTHERS 172 9.3.1.5 INTERFERONS 172 9.3.1.5.1 ALPHA 172 9.3.1.5.2 BETA 172 9.3.1.5.3 GAMMA 173 9.3.1.6 GP41 173 9.3.1.6.1 ENFUVIRTIDE 173 9.3.1.6.2 OTHERS 173 9.3.2 PROTEASE 174 9.3.2.1 ATAZANAVIR 174 9.3.2.2 DARUNAVIR 174 9.3.2.3 LOPINAVIR 174 9.3.2.4 RITONAVIR 174 9.3.2.5 SAQUINAVIR 174 9.3.2.6 INDINAVIR 174 9.3.2.7 NELFINAVIR 175 9.3.2.8 TIPRANAVIR 175 9.3.2.9 AMPRENAVIR 175 9.4 HEPATITIS C VIRUS 175 9.4.1 NS5B POLYMERASE 176 9.4.1.1 SOFOSBUVIR 176 9.4.1.2 DASABUVIR 176 9.4.2 NS3/4A PROTEASE 177 9.4.2.1 DANOPREVIR 177 9.4.2.2 GLECAPREVIR 177 9.4.2.3 GRAZOPREVIR 177 9.4.2.4 PARITAPREVIR 177 9.4.2.5 SIMEPREVIR 177 9.4.3 NS5A PHOSPHOPROTEIN 178 9.4.3.1 LEDIPASVIR 178 9.4.3.2 VELPATASVIR 178 9.4.3.3 OMBITASVIR 178 9.4.3.4 ELBASVIR 178 9.4.3.5 DACLATASVIR 178 9.4.3.6 PIBRENTASVIR 178 9.4.4 NEURAMINIDASE 179 9.4.4.1 OSELTAMIVIR 179 9.4.4.2 ZANAMIVIR 179 9.4.4.3 PERAMIVIR 179 9.4.4.4 LANINAMIVIR 179 9.4.5 RNA POLYMERASE 179 9.4.5.1 BALOXAVIR MARBOXIL 180 9.4.5.2 FAVIPIRAVIR 180 9.4.6 MATRIX PROTEIN 2 180 9.4.6.1 RIMATIDINE 180 9.4.6.2 FAVIPIRAVIR 180 9.5 HERPES SIMPLEX VIRUS 181 9.5.1 DNA POLYMERASE UL30 182 9.5.1.1 ACICLOVIR 182 9.5.1.2 FAMCICLOVIR 182 9.5.1.3 VALACICLOVIR 182 9.5.1.4 PENCICLOVIR TRIFLURIDINE 182 9.5.1.5 BRIVUDINE 182 9.5.1.6 FOSCARNET 182 9.5.1.7 IDOXURIDINE 183 9.5.2 ENVELOPE PROTEINS 183 9.5.2.1 DOCOSANOL 183 9.5.2.2 OTHERS 183 9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 183 9.6.1 GANCICLOVIR 184 9.6.2 VALGANCICLOVIR 184 9.6.3 CIDOFOVIR 184 9.6.4 FOSCARNET 184 9.6.5 FOMIVIRSEN 184 9.7 VARICELLA-ZOSTER VIRUS (VZV) 185 9.7.1 VALACICLOVIR 186 9.7.2 FAMCICLOVIR 186 9.7.3 ACICLOVIR 186 9.7.4 VIDARABINE 186 9.7.5 BRIVUDINE 186 9.8 HEPATITIS B VIRUS 186 9.8.1 ENTECAVIR 187 9.8.2 TENOFOVIR 187 9.8.3 TELBIVUDINE 187 9.8.4 TENOFOVIR ALAFENAMIDE 188 9.8.5 OTHERS 188 9.9 RESPIRATORY SYNCYTIAL VIRUS 188 9.9.1 RNA POLYMERASE 189 9.9.1.1 RIBAVIRIN 189 9.9.1.2 OTHERS 189 9.9.2 FUSION GLYCOPROTEIN 189 9.9.2.1 PALIVIZUMAB 190 9.9.2.2 OTHERS 190 9.10 CORONAVIRUS INFECTION 190 9.11 OTHERS 191 10 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 192 10.1 OVERVIEW 193 10.2 GERIATRIC 196 10.2.1 MALE 196 10.2.2 FEMALE 196 10.3 CHILD 197 10.3.1 MALE 197 10.3.2 FEMALE 198 10.4 ADULT 198 10.4.1 MALE 199 10.4.2 FEMALE 199 11 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS 200 11.1 OVERVIEW 201 11.2 ORAL 204 11.2.1 SOLID 205 11.2.1.1 TABLETS 205 11.2.1.2 CAPSULES 205 11.2.1.3 OTHERS 205 11.2.2 SEMISOLID 205 11.2.2.1 GELS 206 11.2.2.2 EMULSIONS 206 11.2.2.3 ELIXIRS 206 11.2.2.4 OTHERS 206 11.2.3 LIQUID 206 11.2.3.1 SOLUTIONS 206 11.2.3.2 SYRUPS 206 11.2.3.3 OTHERS 206 11.3 TOPICAL 207 11.3.1 SEMI-SOLID 208 11.3.1.1 CREAM 208 11.3.1.2 OINTMENT 208 11.3.1.3 GELS 208 11.3.1.4 OTHERS 208 11.3.2 LIQUID 208 11.3.2.1 SOLUTIONS 209 11.3.2.2 SUSPENSIONS 209 11.3.3 SOLID 209 11.3.3.1 POWDERS 209 11.3.3.2 SUPPOSITORIES 209 11.3.3.3 ENEMA 209 11.3.3.4 OTHERS 209 11.4 PARENTERAL 210 11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 211 11.4.1.1 SOLUTIONS 211 11.4.1.2 RECONSTITUTED/LYOPHILIZED 211 11.4.1.3 SUSPENSIONS 211 11.4.1.4 EMULSIONS 211 11.4.1.5 OTHERS 211 11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 212 11.4.3 COLLOIDAL DISPERSIONS 212 11.4.4 LONG ACTING INJECTION FORMULATION 212 12 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 213 12.1 OVERVIEW 214 12.2 GENERIC 217 12.3 BRANDED 217 13 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER 218 13.1 OVERVIEW 219 13.2 HOSPITAL 222 13.3 SPECIALTY CENTERS 222 13.4 AMBULATORY CENTRES 223 13.5 CLINICS 223 13.6 HOME HEALTHCARE 223 13.7 OTHERS 224 14 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 225 14.1 OVERVIEW 226 14.2 HOSPITAL PHARMACY 229 14.3 RETAIL PHARMACY 229 14.4 ONLINE PHARMACY 230 15 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY REGION 231 15.1 ASIA-PACIFIC 232 15.1.1 JAPAN 254 15.1.2 CHINA 270 15.1.3 SOUTH KOREA 286 15.1.4 INDIA 304 15.1.5 AUSTRALIA 321 15.1.6 SINGAPORE 339 15.1.7 THAILAND 357 15.1.8 MALAYSIA 374 15.1.9 INDONESIA 391 15.1.10 PHILIPPINES 409 15.1.11 VIETNAM 427 15.1.12 REST OF ASIA-PACIFIC 444 16 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 445 16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 445 17 SWOT ANALYSIS 446 18 COMPANY PROFILE 447 18.1 GILEAD SCIENCES, INC. (2022) 447 18.1.1 COMPANY SNAPSHOT 447 18.1.2 REVENUE ANALYSIS 447 18.1.3 COMPANY SHARE ANALYSIS 448 18.1.4 PRODUCT PORTFOLIO 448 18.1.5 RECENT DEVELOPMENT 448 18.2 PFIZER INC. (2022) 449 18.2.1 COMPANY SNAPSHOT 449 18.2.2 REVENUE ANALYSIS 449 18.2.3 COMPANY SHARE ANALYSIS 450 18.2.4 PRODUCT PORTFOLIO 450 18.2.5 RECENT DEVELOPMENTS 450 18.3 SIGA TECHNOLOGIES (2022) 451 18.3.1 COMPANY SNAPSHOT 451 18.3.2 REVENUE ANALYSIS 451 18.3.3 COMPANY SHARE ANALYSIS 452 18.3.4 PRODUCT PORTFOLIO 452 18.3.5 RECENT DEVELOPMENT 452 18.4 GLAXOSMITHKLINE PLC 453 18.4.1 COMPANY SNAPSHOT 453 18.4.2 REVENUE ANALYSIS 453 18.4.3 COMPANY SHARE ANALYSIS 454 18.4.4 PRODUCT PORTFOLIO 454 18.4.5 RECENT DEVELOPMENT 454 18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 455 18.5.1 COMPANY SNAPSHOT 455 18.5.2 REVENUE ANALYSIS 455 18.5.3 COMPANY SHARE ANALYSIS 456 18.5.4 PRODUCT PORTFOLIO 456 18.5.5 RECENT DEVELOPMENT 456 18.6 ABBVIE INC 457 18.6.1 COMPANY SNAPSHOT 457 18.6.2 REVENUE ANALYSIS 457 18.6.3 PRODUCT PORTFOLIO 458 18.6.4 RECENT DEVELOPMENT 458 18.7 AUROBINDO PHARMA (2022) 459 18.7.1 COMPANY SNAPSHOT 459 18.7.2 REVENUE ANALYSIS 459 18.7.3 PRODUCT PORTFOLIO 460 18.7.4 RECENT DEVELOPMENT 460 18.8 AVET PHARMACEUTICALS INC 461 18.8.1 COMPANY SNAPSHOT 461 18.8.2 PRODUCT PORTFOLIO 461 18.8.3 RECENT DEVELOPMENT 461 18.9 BRISTOLL MYERS SQUIBB (2022) 462 18.9.1 COMPANY SNAPSHOT 462 18.9.2 REVENUE ANALYSIS 462 18.9.3 PRODUCT PORTFOLIO 463 18.9.4 RECENT DEVELOPMENT 463 18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 464 18.10.1 COMPANY SNAPSHOT 464 18.10.2 REVENUE ANALYSIS 464 18.10.3 PRODUCT PORTFOLIO 465 18.10.4 RECENT DEVELOPMENT 465 18.11 CIPLA INC. (2022) 466 18.11.1 COMPANY SNAPSHOT 466 18.11.2 REVENUE ANALYSIS 466 18.11.3 PRODUCT PORTFOLIO 467 18.11.4 RECENT DEVELOPMENT 467 18.12 DR. REDDY’S LABORATORIES LTD. (2022) 468 18.12.1 COMPANY SNAPSHOT 468 18.12.2 REVENUE ANALYSIS 468 18.12.3 PRODUCT PORTFOLIO 469 18.12.4 RECENT DEVELOPMENTS 469 18.13 EMERGENT (2022) 470 18.13.1 COMPANY SNAPSHOT 470 18.13.2 REVENUE ANALYSIS 470 18.13.3 PRODUCT PORTFOLIO 471 18.13.4 RECENT DEVELOPMENT 471 18.14 HETERO 472 18.14.1 COMPANY SNAPSHOT 472 18.14.2 PRODUCT PORTFOLIO 472 18.14.3 RECENT DEVELOPMENT 472 18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 473 18.15.1 COMPANY SNAPSHOT 473 18.15.2 REVENUE ANALYSIS 473 18.15.3 PRODUCT PORTFOLIO 474 18.15.4 RECENT DEVELOPMENT 474 18.16 MACLEODS PHARMACEUTICALS LTD 475 18.16.1 COMPANY SNAPSHOT 475 18.16.2 PRODUCT PORTFOLIO 475 18.16.3 RECENT DEVELOPMENT 475 18.17 MERCK & CO., INC, (2022) 476 18.17.1 COMPANY SNAPSHOT 476 18.17.2 REVENUE ANALYSIS 476 18.17.3 PRODUCT PORTFOLIO 477 18.17.4 RECENT DEVELOPMENT 477 18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 478 18.18.1 COMPANY SNAPSHOT 478 18.18.2 REVENUE ANALYSIS 478 18.18.3 PRODUCT PORTFOLIO 479 18.18.4 RECENT DEVELOPMENT 479 18.19 NAVINTA LLC 480 18.19.1 COMPANY SNAPSHOT 480 18.19.2 PRODUCT PORTFOLIO 480 18.19.3 RECENT DEVELOPMENT 480 18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 481 18.20.1 COMPANY SNAPSHOT 481 18.20.2 REVENUE ANALYSIS 481 18.20.3 PRODUCT PORTFOLIO 482 18.20.4 RECENT DEVELOPMENT 482 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 483 18.21.1 COMPANY SNAPSHOT 483 18.21.2 REVENUE ANALYSIS 483 18.21.3 PRODUCT PORTFOLIO 484 18.21.4 RECENT DEVELOPMENT 484 18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 485 18.22.1 COMPANY SNAPSHOT 485 18.22.2 REVENUE ANALYSIS 485 18.22.3 PRODUCT PORTFOLIO 486 18.22.4 RECENT DEVELOPMENTS 486 19 QUESTIONNAIRE 487 20 RELATED REPORTS 490